Aculys Pharma, Inc. was founded as Japan’s first biopharma company based on the philosophy of “Catalyst to Access”. Our goal is to become the leading provider of innovations for neurological diseases in Japan.

Our company was established to address two critical questions that arose during my time working for global pharmaceutical companies. First, I wondered why more wasn’t being done to help Japanese patients get access to more medications—Japan’s drug lag was a significant challenge for its citizens. And second, I wondered what more could be done to address the true needs of Japanese patients, and what was needed to help them live happier, healthier lives. Because medications alone were not enough.

At ACULYS, we are committed to speeding the pathway for medicines approved in other countries to those in need in Japan as quickly as possible. And to address social issues beyond medication, we are creating comprehensive support programs that go beyond the framework of conventional pharmaceutical companies, building partnerships with health tech companies and working to address the broader social factors that impact patients and their families.

With a focus on the unmet medical needs in neurology, ACULYS is leveraging our team’s expertise and agility as a startup to create positive change for patients, their families, healthcare professionals, and society as a whole. At ACULYS, we are dedicated to building a better world for all of those affected by neurological diseases.